Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment

International Journal of Gynecological Pathology

Volumn 18, Issue 4, 1999, Pages 304-309

  Cohen, Ilan ^a   Azaria, Ron ^a   Fishman, Ami ^a   Tepper, Ron ^a   Shapira, Jeremiah ^a,b   Beyth, Yoram ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; Endometrial carcinoma; Menopause; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; VAGINA BLEEDING;

EID: 0032871929     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199910000-00003     Document Type: Article

References (43)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy. Lancet 1992;339:1-15, 71-85.
2. FDA, Zeneca pharmaceuticals warn of increased uterine-cancer risk with tamoxifen treatment. Am J Hosp Pharm 1994;51:1380-1.
3. ACOG Committee Opinion. Tamoxifen and endometrial cancer. Int J Gynecol Obstet 1996;53:197-9.
4. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
5. Fornander T, Cedermak B, Mattson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;I:117-20.
6. Andersson M, Storm H, Mouridsen T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-7.
7. Ryden S, Fermo M, Moller T. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 1992;31:271-4.
8. Fisher B, Costantino JP, Redmond CK, Fisher EB, Wickerham L, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86: 527-37.
9. Rutquist LE, Johnson H, Signomaklo T, Johnson U, Fornander T, Wilking T. Adjuvant tamoxifen therapy for early breast cancer and second primary cancer. J Natl Cancer Inst 1995;87:645-51.
10. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992;31:259-63.
11. Boccardo F, Rubagotti A, Amoroso D. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer 1992; 28:673-80.
12. Ribero G, Swindell R. The Christie Hospital adjuvant tamoxifen trial - status at 10 years. Br J Cancer 1988;50:601-3.
13. Castiglione M, Gelber RD, Goldhirsch A, for the International Breast Cancer Study Group. Adjuvant systemic therapy for breast cancer in the elderly: comparing causes of mortality. J Clin Oncol 1990;8:519-26.
14. Fornander T, Rutquist LE, Cedermark B. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol 1991;9:1740-8.
15. Cummings FJ, Gray R, Tormey DC. et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993;11: 29-35.
16. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88:832-4.
17. Barakat RR, Wong G, Curtin JP, Vlamis MS, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
18. Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 1988;II:1432.
19. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;II:563.
20. Hardell L. Tamoxifen as a risk factor for endometrial carcinoma. Cancer 1990;66:1661.
21. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LA, Gimbrere CH, Otter R. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
22. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J Natl Cancer Inst 1995;87:1359-64.
23. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995;59:186-90.
24. Sasco AJ, Chaplin G, Amoros E, Saez S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radio-therapy. Epidemiology 1996;7:9-13.
25. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
26. Cuenca RE, Giachino J, Arredondo MA, Hempling R. Edge SB. Endometrial carcinoma associated with breast carcinoma. Cancer 1996;77:2058-63.
27. Fornander T, Hellstrom A-C, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85:1850-5.
28. Melfatano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82-4.
29. Silva EG, Carmen ST, Follen-Mitchell M. Malignant neoplasms of the corpus in patients treated for breast carcinoma: the effect of tamoxifen. Int J Gynecol Pathol 1994;13:248-58.
30. Segna RA, Dottino PR, Deligdisch L, Cohen CJ. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416-8.
31. Seoud MA-F, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Gynecol Oncol 1993;82: 165-9.
32. MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol 1997;24:122-139 (Suppl I).
33. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Beyth Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynecol 1993;100:567-70.
34. Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, Cohen I. Value of sonohysterography in asymptomatic, postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997;64:386-91.
35. Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis and treatment. Semin Oncol 1997;24:140-150 (Suppl I).
36. Horwitz RI, Feinstein AR. Estrogen and endometrial cancer: responses to arguments and current status of an epidemiologic controversy. Am J Med 1986;81:503-7.
37. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996;14:434-40.
38. Parrazzini F, La Vecchia C, Bocciolone L. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
39. Furr BA, Jordan VC. The pharmacology and clinical users of tamoxifen. Pharmacol Ther 1984;25:127-205.
40. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-76.
41. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995;1:467-72.
42. Clement PB, Oliva E, Young RH. Mullerian adenosarcoma of the uterus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol 1996;15:222-9.
43. Cohen I, Perel E, Flex D, Teprer R, Altaras MM, Cordoba M, Beyth Y. Endometrial pathologies in postmenopausal tamoxifen treatment: comparison between gynecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-82.